Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1973 Mar;3(3):412–417. doi: 10.1128/aac.3.3.412

Cytosine Arabinoside Therapy for Herpes Simplex Encephalitis—Clinical Experience with Six Patients

Anthony W Chow 1,2,3,4, Allan Ronald 1,2,3,4, Milan Fiala 1,2,3,4, William Hryniuk 1,2,3,4, Marvin L Weil 1,2,3,4, Joseph St Geme Jr 1,2,3,4, Lucien B Guze 1,2,3,4
PMCID: PMC444424  PMID: 4790599

Abstract

Two neonates and four adults with herpes simplex virus (HSV) encephalitis were treated with cytosine arabinoside (Ara-C). A low dose of 40 to 160 mg per m2 per day was given for 4 to 6 days by continuous intravenous infusion and, except in two cases, by intrathecal administration. In one patient, idoxuridine (IUdR) at the dose of 1 g every 4 h was also administered after 4 days of Ara-C therapy. Both neonates and two of four adults survived. Their clinical improvement was closely related in time to the onset of therapy with Ara-C (cases 1, 2, 3) and with IUdR (case 4). In one adult who died on the 27th day of illness of a massive pulmonary embolus, postmortem examination of the brain did not disclose viral inclusions, and viral culture was negative. In the other patient who died, however, brain culture postmortem was still positive for HSV despite 4 days of Ara-C therapy. Ara-C, in addition to IUdR, may be effective in HSV encephalitis treatment, but double-blind, controlled studies appear to be necessary with these agents.

Full text

PDF
412

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen L. B., Sidwell R. W. Target-organ treatment of neurotropic virus diseases: efficacy as a chemotherapy tool and comparison of activity of adenine arabinoside, cytosine arabinoside, idoxuridine, and trifluorothymidine. Antimicrob Agents Chemother. 1972 Sep;2(3):229–233. doi: 10.1128/aac.2.3.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BUTHALA D. A. CELL CULTURE STUDIES ON ANTIVIRAL AGENTS. I. ACTION OF CYTOSINE ARABINOSIDE AND SOME COMPARISONS WITH 5-IODO-2-DEOXYURIDINE. Proc Soc Exp Biol Med. 1964 Jan;115:69–77. doi: 10.3181/00379727-115-28834. [DOI] [PubMed] [Google Scholar]
  3. CALABRESI P., CARDOSO S. S., FINCH S. C., KLIGERMAN M. M., VON ESSEN C. F., CHU M. Y., WELCH A. D. Initial clinical studies with 5-iodo-2'-deoxyuridine. Cancer Res. 1961 May;21:550–559. [PubMed] [Google Scholar]
  4. Campbell A. M. Herpes encephalitis. I. The clinical picture. Postgrad Med J. 1969 Jun;45(524):382–385. doi: 10.1136/pgmj.45.524.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Evans A. D., Gray O. P., Miller M. H., Jones E. R., Weeks R. D., Wells C. E. Herpes simplex encephalitis treated with intravenous idoxuridine. Br Med J. 1967 May 13;2(5549):407–410. doi: 10.1136/bmj.2.5549.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farris W. A., Blaw M. E. Cytarabine treatment of herpes simplex encephalitis. Arch Neurol. 1972 Aug;27(2):99–102. doi: 10.1001/archneur.1972.00490140003002. [DOI] [PubMed] [Google Scholar]
  7. Fiala M., Chow A., Guze L. B. Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains. Antimicrob Agents Chemother. 1972 Apr;1(4):354–357. doi: 10.1128/aac.1.4.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goldman B., Nahor A., Braham J., Padeh B. Herpes encephalitis treated with idoxuridine. Lancet. 1970 Jul 18;2(7664):155–156. doi: 10.1016/s0140-6736(70)92743-1. [DOI] [PubMed] [Google Scholar]
  9. Ho D. H., Frei E., 3rd Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944–954. doi: 10.1002/cpt1971126944. [DOI] [PubMed] [Google Scholar]
  10. Hughes W. F. Treatment of herpes simplex keratitis. A review. Am J Ophthalmol. 1969 Mar;67(3):313–328. doi: 10.1016/0002-9394(69)92040-6. [DOI] [PubMed] [Google Scholar]
  11. Juel-Jensen B. E. Severe generalized primary herpes treated with cytarabine. Br Med J. 1970 Apr 18;2(5702):154–155. doi: 10.1136/bmj.2.5702.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Juel-Jensen B. E. Varicella and cytosine arabinoside. Lancet. 1970 Mar 14;1(7646):572–572. doi: 10.1016/s0140-6736(70)90815-9. [DOI] [PubMed] [Google Scholar]
  13. McKelvey E. M., Kwaan H. C. Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia. Blood. 1969 Nov;34(5):706–711. [PubMed] [Google Scholar]
  14. Miller J. D., Ross C. A. Encephalitis. A four-year survey. Lancet. 1968 May 25;1(7552):1121–1126. doi: 10.1016/s0140-6736(68)90188-8. [DOI] [PubMed] [Google Scholar]
  15. Nahmias A. J., Alford C. A., Korones S. B. Infection of the newborn with herpesvirus hominis. Adv Pediatr. 1970;17:185–226. [PubMed] [Google Scholar]
  16. Nolan D. C., Carruthers M. M., Lerner A. M. Herpesvirus hominis encephalitis in Michigan. Report of thirteen cases, including six treated with idoxuridine. N Engl J Med. 1970 Jan 1;282(1):10–13. doi: 10.1056/NEJM197001012820103. [DOI] [PubMed] [Google Scholar]
  17. Olson L. C., Buescher E. L., Artenstein M. S., Parkman P. D. Herpesvirus infections of the human central nervous system. N Engl J Med. 1967 Dec 14;277(24):1271–1277. doi: 10.1056/NEJM196712142772401. [DOI] [PubMed] [Google Scholar]
  18. Prager D., Bruder M., Sawitsky A. Disseminated varicella in a patient with acute myelogenous leukemia: treatment with cytosine arabinoside. J Pediatr. 1971 Feb;78(2):321–323. doi: 10.1016/s0022-3476(71)80022-7. [DOI] [PubMed] [Google Scholar]
  19. UNDERWOOD G. E., WISNER C. A., WEED S. D. CYTOSINE ARABINOSIDE (CA) AND OTHER NUCLEOSIDES IN HERPES VIRUS INFECTIONS. Arch Ophthalmol. 1964 Oct;72:505–512. doi: 10.1001/archopht.1964.00970020505014. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES